Propanc Biopharma, Inc.: Form 10-Q for the period ended Mar 31, 2017
Filed with the SEC on May 8, 2017 and accepted by EDGAR at May 8, 2017, 17:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-01-01 to 2017-03-31 | $386.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2016-07-01 to 2017-03-31 | $714.9k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-01-01 to 2017-03-31 | −$1.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2016-07-01 to 2017-03-31 | −$4.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-01-01 to 2017-03-31 | $798.4k | us-gaap:InterestExpense |
| Interest expense | 9 months2016-07-01 to 2017-03-31 | $2.5m | us-gaap:InterestExpense |
| Income tax | 3 months2017-01-01 to 2017-03-31 | −$306.2k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2016-07-01 to 2017-03-31 | −$306.2k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-01-01 to 2017-03-31 | −$1.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2016-07-01 to 2017-03-31 | −$6.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-01-01 to 2017-03-31 | −$0.38 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2016-07-01 to 2017-03-31 | −$1.86 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2016-07-01 to 2017-03-31 | −$1.4m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | At period end2017-03-31 | $9.1k | us-gaap:Cash |
| Current assets | At period end2017-03-31 | $31.2k | us-gaap:AssetsCurrent |
| Total assets | At period end2017-03-31 | $44.8k | us-gaap:Assets |
| Current liabilities | At period end2017-03-31 | $4.8m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2017-03-31 | $2.7m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2017-03-31 | −$4.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-17-004870. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.